 NEW YORK, Sept. 21, 2022 GLOBE NEWSWIRE -- Immunovant, Inc. Nasdaq: IMVT, a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will present a corporate update at Roivants Investor Day, taking place on September 28th, 2022. 